H. L. Ormond & Company, LLC Outlook Therapeutics, Inc. Transaction History

H. L. Ormond & Company, LLC

  • $62.4 Million
  • Q3 2022

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 11, 2022
SELL
$1.22 - $2.03 $12,200 - $20,299
-10,000 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$1.27 - $2.23 $12,700 - $22,300
10,000 New
10,000 $13,000

Others Institutions Holding OTLK

# of Institutions
3
Shares Held
31.5K
Call Options Held
0
Put Options Held
0
View Full List

About Outlook Therapeutics, Inc.

OTLK Quotes by TradingView
  • Ticker OTLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 226,144,992
  • Market Cap $1.47B
  • Description
  • Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...
More about OTLK
Track This Portfolio

Track H. L. Ormond & Company, LLC Portfolio

Follow H. L. Ormond & Company, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of H. L. Ormond & Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on H. L. Ormond & Company, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email